AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03557294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg Varenicline b.i.d.
Description: Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
Study NCT03557294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.0mg placebo Varenicline b.i.d.
Description: Product that looks like active varenicline, but contains no active ingredient
Study NCT01510483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity Prevention
Description: Those in the experimental, obesity prevention, condition will be exposed to the office-wide intervention for diet and activity. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
Study NCT02442492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
Study NCT02442492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
Study NCT00418626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study NCT02002650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-ERCP rectal Indomethacin
Description: Rectal Indomethacin was administrated within 30min before ERCP in all patients.
Study NCT02002650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-operational Rectal Indomethacin
Description: Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
Study NCT01510483 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Prevention
Description: Those in the control, tobacco prevention, condition will be exposed to the office-wide intervention for avoidance of tobacco and second hand smoke. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
Study NCT03531970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine
Description: Anesthetic solution
Study NCT03531970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2% lidocaine with 1:80,000 epinephrine
Description: Anesthetic solution
Study NCT03531970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Corticostroide
Study NCT03531970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00552877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (Xience V stent)
Description: Cypher Select plus coronary stent Xience V coronary stent
Study NCT04123574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talabostat Mesylate
Description: BXCL701 tablets dosage strengths include 0.2mg and 0.05mg tablets for oral administration.~Patients are to self-administer the prescribed number of BXCL701 tablets for a total daily dose of 0.6 mg. BXCL701 should not be taken on an empty stomach.~Daily blood pressure monitoring will be performed during the dosing period. Administration of at least 1L of intravenous (IV) fluids is required on Day 1.~On days when pharmacokinetic (PK) assessments are being performed, BXCL701 should be administered at the study center and should be administered at (approximately) the same time of day on each treatment day.
Study NCT01405326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40mg sc. every two weeks for six months
Study NCT01405326 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: adalimumab
Description: 40mg sc. every two weeks for six months
Study NCT04074863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Darrach
Description: Surgical treatment of painful DRU osteoarthritis with resection of distal ulna
Study NCT04074863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis
Description: Surgical treatment of painful DRU osteoarthritis with distal ulna replacement with Herbert implant
Study NCT02648165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Computer based Attention Bias Modification
Study NCT02648165 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Attention Bias Modification
Description: Computer based Sham Attention Bias Modification
Study NCT02648165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy delivered in a group therapy setting
Study NCT02648165 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy delivered in a group therapy setting
Study NCT03312452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hospira plum pump
Description: The Hospira plum pump enables the clinician to program a specific volume of intravenous fluid and define a period of time over which to administer this fluid.
Study NCT03312452 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gravity drip device
Description: Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
Study NCT00091169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: levocarnitine
Description: Given orally
Study NCT00091169 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT03191500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: steerable catheter
Description: peripheral vascular disease
Study NCT02747641 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pixel CO2 Laser System
Study NCT00289432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducative
Description: The experimental group consists of five weekly 2-hours sessions, focusing on coping with diagnosis and treatment
Study NCT00289432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support group
Description: Standard Hospital follow-up support group
Study NCT01550445 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Prednisolone
Description: Those patients who fulfill the entry criteria enter in this prospective controlled trial of steroid withdrawal starting at three months after transplantation
Study NCT00661479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 µg Brimonidine Tartrate Implant
Description: 400 µg brimonidine tartrate implant in the study eye on Day 1.
Study NCT00661479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 µg Brimonidine Tartrate Implant
Description: 200 µg brimonidine tartrate implant in the study eye on Day 1.
Study NCT00661479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 µg Brimonidine Tartrate Implant
Description: 100 µg brimonidine tartrate implant in the study eye on Day 1.
Study NCT00661479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham (no implant)
Description: Sham in the fellow eye on Day 1.
Study NCT00508703 — intervention group
Intervention type: RADIATION
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: Dose of 45Gy
Study NCT00508703 — intervention group
Intervention type: PROCEDURE
Intervention: CT Scan
Description: CT Scans: Twice a week during the 5 weeks of radiation treatment.
Study NCT03372707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cuff Leak Test
Description: The Respiratory Therapist (RT) will perform the CLT on all enrolled patients. The patients will first be switched to volume assist-control (V-AC) with a respiratory rate of 10 breaths/min (to allow patient assist), constant flow of 60 l/min, and tidal volume set to match the average tidal volume currently being delivered during supportive ventilation. The RT will document the average exhaled volume over 3-5 breaths after switching to V-AC. The test will be performed by deflating the ETT balloon cuff with a 10 cc syringe, and: a) auscultation with a stethoscope to identify audible air leak around the ETT, and b) measuring the difference between the average exhaled volume prior to cuff deflation and the average exhaled volume over 3-5 breaths after cuff deflation.
Study NCT00110110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given after chemo cycle for 7 days or until neutrophil counts return to normal.
Study NCT00110110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given at 28 mg/kg/dose.
Study NCT00110110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given at 33 mg/kg/dose
Study NCT00110110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given at 12 mg/kg/dose
Study NCT00110110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given at 0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated
Study NCT00110110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryosurgery
Description: Local application of extreme cold to destroy residual tumor.
Study NCT00110110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: Local and precise application of laser beams to destroy residual tumor.
Study NCT00206661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: 4 mcg sargramostim with and without corticosteroids
Study NCT02584686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: The treatment group will be injected intracavernously with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for colour Doppler assessment, followed next day by 50 units of BTX-A.
Study NCT02584686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.
Study NCT00206661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: 6 mcg sargramostim with and without corticosteroids
Study NCT01004068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SET-diet plus clomiphene
Description: Two months of structured exercise program plus hypocaloric diet followed by 150 mg daily of clomiphene citrate
Study NCT01004068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: Clomiphene citrate at 150 mg daily for one cycle
Study NCT01004068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise program plus hypocaloric diet
Description: SET plus diet
Study NCT03898544 — intervention group
Intervention type: DEVICE
Intervention: Group primary TKA
Description: Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors (IR) on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking).
Study NCT03898544 — intervention group
Intervention type: DEVICE
Intervention: Group TKA revision
Description: Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking).
Study NCT01954498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnuts
Study NCT03857620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT03857620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive OPTI-Surg program materials
Study NCT03857620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01954498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OTC multivitamin
Study NCT01253837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNFa
Description: Phase I: Sequential assignment of Patient cohorts to one of six dose levels of L19TNFa: 1.3, 2.6, 5.2, 7.8, 10.4, 13.0 µg/kg.~Phase II: The Recommended Dose (RD) of 13.0 µg/kg of L19TNFα determined in Phase I.~Schedule: Infusions of L19TNFα on days 1, 3 and 5 of each 21-day cycle. Patients may remain on treatment for a maximum of six 21-day cycles.
Study NCT00656513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine
Description: 5mg by mouth 3 times a day for 12 weeks
Study NCT00656513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALTENS
Description: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit
Study NCT02991222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPARC001 type I
Description: Treatment type I
Study NCT03857620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02991222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC001 type I
Description: Treatment type I
Study NCT02991222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPARC001 type II
Description: Treatment type II
Study NCT02991222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC001 type II
Description: Treatment type II
Study NCT02991222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference001 type I
Description: Hydrocodone-Acetaminophen
Study NCT02991222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference001 type I
Description: Hydrocodone-Acetaminophen
Study NCT02991222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference001 type II
Description: Hydrocodone-Acetaminophen
Study NCT02991222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference001 type II
Description: Hydrocodone-Acetaminophen
Study NCT01479296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)
Description: Given intramuscularly
Study NCT01479296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5 env A
Description: Given intramuscularly
Study NCT01479296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5 env B
Description: Given intramuscularly
Study NCT01479296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5 env C
Description: Given intramuscularly
Study NCT01479296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5 gag-pol
Description: Given intramuscularly
Study NCT01479296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Vaccine
Description: Given intramuscularly
Study NCT03992560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guide CRT Software Prototype
Description: The medical device in the trial is a software programme that allows image fusion of previously acquired MRI images with real-time X-Ray fluoroscopic images in the cardiac catheter laboratory. We are able to use the MRI information to assess the best location to place the left ventricular lead for a CRT device and then superimpose this location onto the real-time X-Ray fluoroscopic images during the left ventricular lead implantation
Study NCT01185236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin/ezetimibe
Description: simvastatin/ezetimibe 10/20mg once daily for 12weeks
Study NCT01185236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 20mg
Description: atorvastatin 20mg once daily for 12weeks
Study NCT03137381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Administered as tablets.
Study NCT03137381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CTP-543 matching placebo
Description: Administered as tablets.
Study NCT03298334 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Seeding
Description: A gauze containing the Mother's vaginal flora will be swabbed over the face and body of the neonate shortly after cesarean delivery.
Study NCT03298334 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Vaginal Seeding
Description: A gauze carrying sterile saline will be swabbed over the face and body of the neonate shortly after cesarean delivery.
Study NCT00459316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent meningococcal conjugate vaccine
Description: MCV4 vaccine (4 µg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 µg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than three times for each participant, depending on adverse reactions.
Study NCT03401346 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: INP104
Description: Dihydroergotamine Mesylate (DHE) administered via I123 Precision Olfactory Delivery (POD) Device
Study NCT03401346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroergotamine Mesylate (DHE)
Description: Dihydroergotamine Mesylate (DHE) injection (intravenous)
Study NCT03401346 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Migranal Nasal Spray
Description: Dihydroergotamine Mesylate (DHE) delivered via Migranal Nasal Spray pump
Study NCT01722617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Patients in groups 2 and 3 will be asked to fill in questionnaires FLARE.
Study NCT01750151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose Beverage
Study NCT01750151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Game Playing
Study NCT01750151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Beverage
Study NCT03044106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CLRT
Description: CLRT is a novel method of laser stimulation on specific cranial reflex points that modulate muscle tone.
Study NCT03044106 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CLRT
Description: CLRT is a novel method of laser stimulation on specific cranial reflex points that modulate muscle tone.
Study NCT03857620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention with Coaching
Description: Receive OPTI-Surg program materials plus individual coaching
Study NCT04552977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluzoparil
Description: a PARP1 inhibitor
Study NCT04552977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: an alkylating chemotherapeutic agent
Study NCT04719884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative fluid optimisation
Description: In case of stroke volume variation (SVV) >10% and SI and CI >10% below the starting value, fluid challenge was performed with approximately 2 ml/kg of colloid over maximum of 5 minutes. The response was monitored.~If there was a fall in SVV and an increase in SI of >10% and the SVV still >10%, the second fluid challenge was performed.~If there was still a reduction in SVV after the second fluid challenge, but an increase in nSI \<10% and decrease in systemic vascular resistance (SVR), no additional fluids were given. Vasoactive drugs were used instead.
Study NCT02343874 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be done. The exposure of interest in this study is alcohol consumption in patients attended in primary health.
Study NCT01135537 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (rATG)
Description: Thymoglobulin 2.5 mg/kg of body weight IV administered daily for 3 days prior to HSCT.~Thymoglobulin infused over a minimum of 6 hours for the first infusion and over at least 4 to 6 hours on subsequent days of therapy.
Study NCT02819466 — intervention group
Intervention type: DEVICE
Intervention: 3D echography
Description: ultrasound visualization of the stomach in fasting patients.
Study NCT02940405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: A 10 mg tablet of the medication will be given one hour before starting the root canal treatment